Abstract
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb) and is the leading cause of death. Bacillus Calmette-Guérin (BCG) is the only licensed TB vaccine. Preclinical studies have shown that in adults intravenous administration of BCG improves protection against TB. We hypothesize that intradermal administration of BCG to the human newborn leads to low grade BCG bacteraemia and that this systemic dissemination improves protection against Mtb infection. This hypothesis is based on supporting observations including animal and human studies. It is a testable hypothesis and offers to deliver immediately actionable insight to advance the global efforts against TB.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call